FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.386,50 +408,31 (+0,69%)
Daré Bioscience, Inc. (DARE)
Dopo ore:
| Chiusura precedente | 0,2892 |
| Aperto | 0,2880 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,2880 - 0,3084 |
| Intervallo di 52 settimane | 0,2700 - 1,1000 |
| Volume | |
| Media Volume | 443.592 |
| Capitalizzazione | 30,768M |
| Beta (5 anni mensile) | 1,21 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,3500 |
| Prossima data utili | 09 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 4,67 |
GlobeNewswireDaré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Females 12 Years or Older
Daré to receive $1.8 million payment; eligible for additional potential milestone payments of up to $180 million and tiered double-digit royalties based on net salesSAN DIEGO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the first shipment of XACIATOTM [pronounced zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% in connection with the first commercial sale of the product in the United States, triggering a $1
- GlobeNewswire
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it will receive a payment of approximately $4.5 million as the latest installment under a grant agreement to advance the development of Daré’s investigational contraceptive DARE-LARC1 through nonclinical proof of principle studies and other IND-enabling work to allow for the submission of an Investigational New Drug (IND) Application with the FDA, approval of
- GlobeNewswire
Daré Bioscience to Present at The Menopause Society 2023 Annual Meeting
SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Dr. Andrew Goldstein, Daré Medical Advisor, will present at the 2023 Annual Meeting of The Menopause Society (formerly known as The North American Menopause Society, or NAMS) taking place September 27-30, 2023 at the Marriott Downtown in Philadelphia, PA. Additionally, three poster presentations relating to two of Daré’s investigational products designed
